Morning Recap: Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) – The Daily Leicester

This post was originally published on this site

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a large market cap stock with a market cap of 29.61B. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 166.79, a forward P/E of 39.95 and EPS of 0.71. At a stock price of 118.09 (1.60%) it has a dividend yield of (Data Not Available).

EPS growth for the last five years have been -39.40%, more recently this last year it has grown by 80.10%. The next year growth is going to be about 83.72% and more long-term 64.51% after five years. EPS growth quarter over quarter is 683.50%. Sales growth for the past five years have been 3.80% and sales growth quarter over quarter is 79.50%.

For performance, Vertex Pharmaceuticals Incorporated the past week has seen a gain of 1.25%. For the last month performance for Vertex Pharmaceuticals Incorporated is 2.86%. While the last quarter is 32.82% and half year, 28.36%. Finally for the year, performance is 43.77%.

The 52-week high for Vertex Pharmaceuticals Incorporated, is at -3.17%, and for the 52-week low it comes to a value of 65.25%. The 20-day simple moving average is 1.24% and 28.54% for the 200-day simple moving average.

Volatility for the week is at 2.10%, and for the month it is 2.28%. Vertex Pharmaceuticals Incorporated, has a target price of 123.71.

In terms of debt, long term debt/equity is 0.35, and for total debt/equity Vertex Pharmaceuticals Incorporated has 0.37. The gross margin is 89.90%, while operating margin is 14.60%, the profit margin is 8.80%. The current ratio is 3.8 and the quick ratio is 3.7.

Insider ownership is at 0.50%, with instituitional ownership at 97.90%. Vertex Pharmaceuticals Incorporated has a payout ratio of 0.00%. With the total shares outstanding coming to 250.72. The shares float is 247.24, with the float short at 2.22%, with short ratio coming to 2.93.

In terms of returns, the return on assets see Vertex Pharmaceuticals Incorporated, get 6.40%, with its returns on investment at -0.30%. Return on equity is 15.20%. So will the investors see the target price of 123.71, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

This post was originally published on *this site*